Pfizer Settles With Shareholders Over Celebrex, Bextra Risks

Pfizer has reached a tentative settlement with shareholders to end a class action suit alleging the company minimized the cardiovascular risks of taking Celebrex and Bextra.

Pfizer spokeswoman Neha Wadhwa said that Pfizer has struck “an agreement-in-principle to resolve this securities class action case for all defendants.” 

As part of the settlement, the company denies any guilt, but the remaining terms will be kept confidential until the deal is finalized, the spokeswoman said.